Pardes Biosciences, Inc. (PRDS) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Carlsbad, CA, 美国. 现任CEO为 Thomas G. Wiggans.
PRDS 拥有 IPO日期为 2021-12-27, 57 名全职员工, 在 NASDAQ Global Market, 市值为 $135.19M.
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
